# Karyopharm Expanded Access Program for Selinexor

> **NCT07215832** · — · AVAILABLE · sponsor: **Karyopharm Therapeutics Inc**

## Conditions studied

- Multiple Myeloma
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Sarcoma
- Neuroglioblastoma
- Peripheral T-cell Lymphoma
- Endometrial Cancer
- Myelofibrosis
- Other

## Interventions

- **DRUG:** selinexor

## Key facts

- **NCT ID:** NCT07215832
- **Lead sponsor:** Karyopharm Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07215832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07215832, "Karyopharm Expanded Access Program for Selinexor". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07215832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*